- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Glucotrack, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.07. | Glucotrack Gains Slightly on Bridge Financing Deal | - | Baystreet.ca | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 17.07. | Glucotrack completes bridge financing after merger | 1 | Investing.com | ||
| 17.07. | Glucotrack schließt Brückenfinanzierung nach Unternehmenszusammenschluss ab | 2 | Investing.com Deutsch | ||
| 17.07. | GlucoTrack (GCTK) Stock Rallies 16% After Hours: Here's What Is Going On | 2 | Benzinga.com | ||
| 16.07. | Glucotrack completes business combination with Lokahi Therapeutics | 3 | Investing.com | ||
| 15.07. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Glucotrack combines with Lokahi Therapeutics to become CBGM subsidiary | - | MassDevice | ||
| 14.07. | Glucotrack, Inc.; Lokahi Therapeutics: Glucotrack and Lokahi Therapeutics Complete Strategic Business Combination, Establishing Lokahi-Controlled Public Platform | 207 | GlobeNewswire (Europe) | RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lokahi Therapeutics... ► Artikel lesen | |
| 27.05. | Glucotrack CEO explains tech behind long-term CBGM implant | 12 | MassDevice | ||
| 15.05. | Glucotrack reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 582 | GlobeNewswire (Europe) | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| 14.05. | Glucotrack, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Glucotrack, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 07.05. | Glucotrack submits long-term implantable CBGM for FDA IDE | - | MassDevice | ||
| 07.05. | Glucotrack beantragt FDA-Zulassung für implantierbaren Blutzuckermonitor | 4 | Investing.com Deutsch | ||
| 07.05. | Glucotrack, Inc.: Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology | 248 | GlobeNewswire (Europe) | RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.04. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | Glucotrack, Inc.: Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology | 2 | GlobeNewswire (USA) | ||
| 21.04. | Glucotrack veröffentlicht Peer-Review-Studie zur Langzeitstabilität seines Glukosesensors | 3 | Investing.com Deutsch |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,750 | +0,44 % | EQS-News: Eckert & Ziegler SE: BaFin-Prüfung betrifft Bilanzierung der Pentixapharm-Abspaltung im Konzernabschluss 2024 - möglicher Gewinn aus aufgegebenem Geschäftsbereich ohne Auswirkung auf operative Kennzahlen | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Sonstiges
BaFin-Prüfung betrifft Bilanzierung der Pentixapharm-Abspaltung im Konzernabschluss 2024 - möglicher Gewinn aus aufgegebenem... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,078 | +5,38 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -9,84 % | NuGen Medical Devices Inc.: NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms | Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two... ► Artikel lesen | |
| HEALWELL AI | 0,420 | +3,83 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn Wound Irrigation Solution | BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k)... ► Artikel lesen | |
| UNIDOC HEALTH | 0,050 | -6,72 % | UniDoc Health Corp.: UniDoc Connect Surpasses One Million Patient Visits | Company Records 250,000 Patient Visits in First Six Months Since AMD Purchase, Then Triples to 750,000 in the Following Six Months VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,400 | -0,71 % | EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test | ||
| MEDIVOLVE | - | - | Medivolve Inc (2): OSC cites Bharti, Said for disclosure failures | ||
| QUEST DIAGNOSTICS | 206,50 | -0,34 % | ROUNDUP: Quest Diagnostics Boosts FY26 Outlook; Shares Up 5.7% | WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Thursday, diagnostic services firm Quest Diagnostics, Inc. (DGX) raised its earnings, adjusted earnings and... ► Artikel lesen | |
| QUIDELORTHO | 15,250 | +4,20 % | QuidelOrtho Corporation: QuidelOrtho Appoints Micah Young as Chief Financial Officer | Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq:... ► Artikel lesen | |
| VERU | 2,220 | -0,45 % | Veru Inc.: Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients - -- Interim analysis results on track for calendar Q1 '27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc.... ► Artikel lesen | |
| LIFEWARD | 7,110 | 0,00 % | Lifeward Ltd.: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing | HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| SENSEONICS | 4,440 | +3,26 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen |
GLUCOTRACK INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,08 % bei einem Aktienkurs von 0,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.